Clinical Trial

Metformin Hydrochloride in Combination With Standard of Care Systemic Therapy in Previously Untreated Advanced Unresectable or Metastatic Soft Tissue Sarcoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this research study is to see how metformin, when used in combination with standard of care (SOC) treatment for metastatic (cancer that has spread) soft tissue sarcoma can improve patient outcomes.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-12-17; most recent amendment 2026-07-21.
Status change: Not Yet Recruiting → Recruiting 2026-03-04
Trial Details
NCT Number NCT07291297
Lead Sponsor Wake Forest University Health Sciences
Collaborators: Atrium Health Levine Cancer Institute, Paula Takacs Foundation
Conditions Sarcoma Metastatic, Sarcoma, Soft Tissue
Enrollment 50 participants
Start Date 2026-03-04
Primary Completion 2028-10 (estimated)
Study Completion 2033-10 (estimated)
Updated on ClinicalTrials.gov 2026-07-23